Upstream Bio (UPB) news
Recent news
Upstream Bio, Inc.: Truist Securities cuts target price to $25 from $43
AInvest Wire · Aug 12, 2026Upstream Bio Inc Q2 income from operations USD -42.368 million
AInvest Wire · Aug 11, 2026Upstream Bio Inc Q2 collaboration revenue USD 773 thousand
AInvest Wire · Aug 11, 2026Upstream Bio Inc: JP Morgan cuts to neutral from overweight; cuts target price to $8 from $35
J.P. Morgan has downgraded its rating for Upstream Bio Inc. (NASDAQ: UPB) from "Overweight" to "Neutral," while simultaneously reducing its target price from $35 to $8. This move reflects a shift in the firm’s outlook for the clinical-stage biotechnology company, which is developing verekitug, a…
AInvest Wire · Jun 12, 2026Upstream Bio, Inc. <UPB.O>: H.C. Wainwright initiates coverage with buy rating
Upstream Bio, Inc. : H.C. Wainwright initiates coverage with buy rating
AInvest Wire · Jun 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.